Abstract:Despite advances in our understanding of molecular aspects of oncogenesis, cancer remains a leading cause of death. The malignant behavior of a cancer cell is driven by the inappropriate activation of transcription factors. In particular, signal transducers and activators of transcription (STATs), which regulate many critical cellular processes such as proliferation, apoptosis, and differentiation, are frequently activated inappropriately in a wide spectrum of human cancers. Multiple signaling pathways converge on the STATs, highlighting their importance in the development and progression of oncogenic diseases. STAT3 and STAT5 are two members of the STAT protein family that are the most frequently activated in cancers and can drive cancer pathogenesis directly. The development of inhibitors targeting STAT3 and STAT5 has been the subject of intense investigations in the last decade, although effective treatment options remain limited. In this review, we investigate the specific roles of STAT3 and STAT5 in normal physiology and cancer biology, discuss the opportunities and challenges in pharmacologically targeting STAT proteins and their upstream activators, and offer insights into novel therapeutic strategies to identify STAT inhibitors as cancer therapeutics.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the targeting strategies for STAT (signal transducer and activator of transcription) transcription factors in cancer treatment and their clinical translation. Specifically, the paper focuses on how to develop effective drugs to inhibit STAT3 and STAT5, which are abnormally activated in a variety of human cancers, in the hope of finding a new generation of more effective and less toxic cancer treatment methods. The paper explores the specific roles of STAT3 and STAT5 in normal physiology and cancer biology, discusses the opportunities and challenges of pharmacologically targeting these proteins and their upstream activators, and provides insights into new strategies for identifying STAT inhibitors as cancer treatment means. ### Key Point Summary: - **Problem Background**: Although progress has been made in understanding the molecular mechanisms of cancer, cancer remains one of the leading causes of death. The malignant behavior of cancer cells is driven by the improper activation of transcription factors, especially members of the STAT family, which regulate many key cellular processes such as proliferation, apoptosis, and differentiation and are frequently abnormally activated in a variety of human cancers. - **Objective**: Develop inhibitors for STAT3 and STAT5, which are often abnormally activated in cancer and directly drive the occurrence and development of cancer. - **Method**: The paper reviews the current knowledge about STAT function in cancer, as well as the progress and challenges in developing drugs targeting these proteins. - **Significance**: By targeting STAT3 and STAT5, it is expected to develop more effective cancer treatment methods with fewer side effects, thereby improving the treatment outcomes and quality of life of cancer patients. ### Formulas and Mechanisms Involved: - **STAT Activation Mechanism**: STATs usually exist as inactive dimers in the cytoplasm. When they are phosphorylated on a tyrosine residue at the carboxyl terminus, a conformational change occurs, resulting in reciprocal phosphotyrosine - SH2 interactions, which reveals a nuclear localization signal, allowing the STAT dimer to move from the cytoplasm to the nucleus and bind to specific 9 - or 10 - base - pair motifs in the regulatory regions of target genes. - **STAT Inhibition Mechanism**: The activation and nuclear translocation of STATs occur within seconds after cytokine stimulation, but they are also rapidly inactivated through multiple mechanisms, including the actions of protein tyrosine phosphatases (PTPs), protein inhibitors (PIAS), and suppressors of cytokine signaling (SOCS). ### Conclusion: The paper emphasizes the importance and potential of STAT3 and STAT5 as cancer treatment targets, while also pointing out the challenges in the development of related drugs, such as how to ensure drug selectivity and reduce the impact on normal cells. Through in - depth research on the functions and regulatory mechanisms of STATs, important theoretical bases and technical supports can be provided for the development of new cancer treatment methods.

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Structure, Function, Signaling Pathways and Clinical Therapeutics: the Translational Potential of STAT3 As a Target for Cancer Therapy

Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

Targeting STAT3 in Cancer Immunotherapy

STAT signaling as a target for intervention: from cancer inflammation and angiogenesis to non-coding RNAs modulation

Targeting Key Proteins Involved in Transcriptional Regulation for Cancer Therapy: Current Strategies and Future Prospective.

Revisiting Signal Transducer and Activator of Transcription 3 (STAT3) As an Anticancer Target and Its Inhibitor Discovery: Where Are We and Where Should We Go?

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy

Targeting STAT3 Enzyme for Cancer Treatment

Research Progress of STAT3-based Dual Inhibitors for Cancer Therapy.

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

Novel activators and small-molecule inhibitors of STAT3 in cancer

Stat3 Inhibitors As Sensitizing Agents For Cancer Chemotherapy

Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives

Small Molecular Inhibitors and Degraders Targeting STAT3 for Cancer Therapy: an Updated Review (from 2022 to 2024)

The STAT Family: Key Transcription Factors Mediating Crosstalk Between Cancer Stem Cells and Tumor Immune Microenvironment.

The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy

Small Molecule Inhibitors of STAT3 for Cancer Therapy